文献速递前列腺癌

新辅助抗雄激素治疗联合或不联合MEK或SRC抑制用于不利风险前列腺癌的2期随机临床试验

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · Eur Urol Oncol · 2025-11-08

这项2期随机试验将45例接受前列腺切除术的不利风险前列腺癌患者按1:1:1随机分配,接受6-8周新辅助ADT(恩扎卢胺+地加瑞克)单药或联合SRC抑制剂(达沙替尼)或MEK抑制剂(曲美替尼)。主要终点为术后免疫组化EMT标志物(N-钙黏蛋白和波形蛋白)丰度;结果显示各治疗组间无差异,且生化复发时间、睾酮恢复时间或病理学微小残留病灶均无差异。结论认为新辅助SRC或MEK抑制似乎并未减轻ADT诱导的EMT反应,也未影响临床或病理结局。

要点

  • 新辅助ADT联合SRC或MEK抑制未改变术后EMT标志物表达。
  • 三组间生化复发时间、睾酮恢复时间及病理微小残留病灶无差异。
  • 所有组均未发生≥3级治疗相关不良事件。

核心结论

  • 新辅助SRC或MEK抑制似乎并未减轻ADT诱导的EMT反应,也未影响临床或病理结局。

研究设计与样本

  • 2期随机临床试验,45例接受前列腺切除术的不利风险前列腺腺癌患者按1:1:1随机分配。
  • 患者需满足ISUP分级组≥3、PSA>20 ng/ml和/或分期≥cT3a。
  • 干预为6-8周新辅助ADT(恩扎卢胺+地加瑞克)单用或联合SRC抑制剂(达沙替尼)或MEK抑制剂(曲美替尼)。

主要发现

  • 治疗后N-钙黏蛋白和波形蛋白的IHC结果在各组间无差异。
  • 生化复发时间、睾酮恢复时间或病理学微小残留病灶均无差异。
  • MAP2K1、MAP2K2和SRC RNA丰度在所有三组中均显著下降。
  • 无患者发生≥3级治疗相关不良事件。

临床怎么用

  • 对于不利风险前列腺癌患者,新辅助ADT基础上联合SRC或MEK抑制未显示可改善EMT标志物或临床病理结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: It is thought that androgen deprivation therapy (ADT) resistance and subsequent prostate cancer progression via epithelial-mesenchymal transition (EMT) is induced by the SRC and MEK pathways. We hypothesized that inhibition of these pathways could reduce EMT. METHODS: In this phase 2 trial, 45 patients undergoing prostatectomy for International Society of Urological Pathology grade group ≥3, prostate-specific antigen >20 ng/ml, and/or stage ≥cT3a localized prostate adenocarcinoma were randomized 1:1:1 to receive 6-8 wk of neoadjuvant ADT (enzalutamide + degarelix) alone or in combination with either an SRC inhibitor (dasatinib) or MEK inhibitor (trametinib). The primary endpoint was the abundance of EMT markers (N-cadherin and vimentin) on immunohistochemistry (IHC) after prostatectomy. Secondary outcomes included clinicopathologic outcomes, changes in EMT markers between biopsy and prostatectomy according to IHC and RNA abundance, and safety. KEY FINDINGS AND LIMITATIONS: IHC results for N-cadherin and vimentin after treatment did not differ by arm. No differences were observed in time to biochemical recurrence, time to testosterone recovery, or pathologic minimal residual disease. MAP2K1, MAP2K2, and SRC RNA abundance decreased significantly in all three arms. No patients experienced a grade ≥3 treatment-related adverse event. CONCLUSIONS AND CLINICAL IMPLICATIONS: Neoadjuvant SRC or MEK inhibition does not appear to mitigate the EMT response to ADT or influence clinical or pathological outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Agrawal R, Weiner AB, Livingstone J, et al. Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial. Eur Urol Oncol. 2025. PMID: 41207813. doi:10.1016/j.euo.2025.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。